tiprankstipranks
American Oncology Network (AONC)
NASDAQ:AONC
US Market

American Oncology Network (AONC) Income Statement

10 Followers

American Oncology Network Income Statement

Last quarter (Q4 2023), American Oncology Network's total revenue was $939.67M, an increase of Infinity% from the same quarter last year. In Q4, American Oncology Network's net income was $-2.22M. See American Oncology Network’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 1.28B$ 1.28B--$ 0.00
Cost of Revenue
$ 1.20B$ 1.20B---
Gross Profit
$ 82.80M$ 82.80M---
Operating Expense
$ 100.71M$ 100.71M$ -2.39M$ -1.63M$ 834.00
Operating Income
$ -49.15M$ -49.15M$ -2.39M$ -1.63M$ -834.00
Net Non Operating Interest Income Expense
$ -5.09M$ -5.09M$ 5.27M$ -639.49K$ 0.00
Other Income Expense
$ 8.52M$ 8.52M$ -8.68M$ -10.67M-
Pretax Income
$ -62.51M$ -62.51M$ 11.56M$ 8.39M$ -834.00
Tax Provision
$ 384.00K$ 384.00K$ 1.03M--
Earnings From Equity Interest Net Of Tax
$ -259.00K$ -259.00K---
Net Income Common Stockholders
$ -5.54M$ -5.54M$ 10.53M$ 8.39M$ -834.00
Basic EPS
$ -1.39$ -1.36$ 0.75-$ 0.00
Diluted EPS
$ -1.39$ -1.36$ 0.75-$ 0.00
Basic Average Shares
$ 8.11M$ 6.69M$ 75.04M-$ 14.05M
Diluted Average Shares
$ 8.11M$ 6.69M$ 75.04M-$ 14.05M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 1.30B$ 1.30B$ -2.39M$ -1.63M$ 834.00
Net Income From Continuing And Discontinued Operation
$ -5.54M$ -5.54M$ 10.53M$ 8.39M$ -834.00
Normalized Income
$ -57.14M$ -49.38M--$ -834.00
Interest Expense
-----
EBIT
$ -56.09M$ -56.09M$ 11.56M$ 8.39M$ -834.00
EBITDA
$ -38.56M$ -38.56M$ 11.56M$ 8.39M$ -834.00
Currency in USD

American Oncology Network Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis